Expert consensus on the clinical application of antibody‐drug conjugates in the treatment of malignant tumors (2021 edition)

doi:10.1002/cai2.8

Cancer Innovation 2022, 1(1): 3-24 https://doi.org/10.1002/cai2.8

Clinical Guideline |

Open Access | Issue | Published: 19 June 2022

Expert consensus on the clinical application of antibody‐drug conjugates in the treatment of malignant tumors (2021 edition)

Keywords:

malignant tumors, antibody‐drug conjugates, monoclonal antibodies, cytotoxic drugs, safety management

Cite this article:

Expert consensus on the clinical application of antibody‐drug conjugates in the treatment of malignant tumors (2021 edition). Cancer Innovation, 2022, 1(1): 3-24. https://doi.org/10.1002/cai2.8

Download citation

EndNote(RIS)

BibTeX

773

Views

Downloads

Citations

Crossref

N/A

WoS

Scopus

N/A

CSCD

Abstract Full text About this article

Abstract

Antibody‐drug conjugates (ADCs) are targeted biological agents composed of a cytotoxic drug linked to a monoclonal antibody through a linker. The monoclonal antibody targets tumor cells and transports small‐molecule cytotoxic drugs for specific delivery and minimal off‐target side effects. It is necessary for clinicians to understand the molecular characteristics and mechanisms of ADCs. Patients' survival mainly depends on the appropriate dose and course of treatment and also on proper management of adverse reactions. This consensus provides a systematic review of commercially available ADCs and further discusses the clinical application and management of ADCs.

Full text

Abstract

Full text

Outline

About this article

Expert consensus on the clinical application of antibody‐drug conjugates in the treatment of malignant tumors (2021 edition)

Abstract

Keywords: malignant tumors, antibody‐drug conjugates, monoclonal antibodies, cytotoxic drugs, safety management

References(67)

Khongorzul

, Ling

, Khan

, Ihsan

, Zhang

. Antibody‐drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3–19. 10.1158/1541-7786.MCR-19-0582

DOI Google Scholar

Gauzy‐Lazo L, Sassoon I, Brun MP. Advances in antibody‐drug conjugate design: current clinical landscape and future innovations. SLAS Discov.2020;25(8):843–68.

DOI Google Scholar

Ricciuti B, Lamberti G, Andrini E, Genova C, De Giglio A, Bianconi V, et al. Antibody‐drug conjugates for lung cancer in the era of personalized oncology. Semin Cancer Biol. 2019;69:268–78.

DOI Google Scholar

Makawita S, Meric‐Bernstam F. Antibody‐drug conjugates: patient and treatment selection. Am Soc Clin Oncol EducBook. 2020;40:105–14.

DOI Google Scholar

Leung D, Wurst JM, Liu T, Martinez RM, Datta‐Mannan A, Feng Y. Antibody conjugates‐recent advances and future innovations. Antibodies (Basel, Switzerland). 2020;9(1):2.

DOI Google Scholar

van de Donk NW, Dhimolea E. Brentuximab vedotin. mAbs. 2012;4(4):458–65.

DOI Google Scholar

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–9.

DOI Google Scholar

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN‐35) in patients with relapsed or refractory systemic anaplastic large‐cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6.

DOI Google Scholar

Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem‐cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet (London, England). 2015;385(9980):1853–62.

DOI Google Scholar

Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2018;378(4):331–44.

DOI Google Scholar

Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non‐Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254–e65.

DOI Google Scholar

Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B‐cell lymphoma. J Clin Oncol. 2020;38(2):155–65.

DOI Google Scholar

Yu B, Liu D. Gemtuzumab ozogamicin and novel antibody‐drug conjugates in clinical trials for acute myeloid leukemia. Biomark Res. 2019;7:24.

DOI Google Scholar

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–6.

Google Scholar

Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60.

DOI Google Scholar

Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de‐novo acute myeloid leukaemia (ALFA‐0701): a randomised, open‐label, phase 3 study. Lancet (London, England). 2012;379(9825):1508–16.

DOI Google Scholar

Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC‐GIMEMA AML‐19 trial. J Clin Oncol. 2016;34(9):972–9.

DOI Google Scholar

Lamb YN. Inotuzumab ozogamicin: first global approval. Drugs. 2017;77(14):1603–10.

DOI Google Scholar

Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53.

DOI Google Scholar

Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018;32(8):1768–77.

DOI Google Scholar

Podar K, Leleu X. Relapsed/refractory multiple myeloma in 2020/2021 and beyond. Cancers (Basel). 2021;13(20):5154.

DOI Google Scholar

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM‐2): a two‐arm, randomised, open‐label, phase 2 study. Lancet Oncol. 2020;21(2):207–21.

DOI Google Scholar

Richardson PG, Lee HC, Abdallah AO, Cohen AD, Kapoor P, Voorhees PM, et al. Single‐agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM‐2 study. Blood Cancer J. 2020;10(10):106.

DOI Google Scholar

Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B‐cell lymphoma (LOTIS‐2): a multicentre, open‐label, single‐arm, phase 2 trial. Lancet Oncol. 2021;22(6):790–800.

DOI Google Scholar

García‐Alonso S, Ocaña A, Pandiella A. Trastuzumab emtansine: mechanisms of action and resistance, clinical progress, and beyond. Trends Cancer. 2020;6(2):130–46.

DOI Google Scholar

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2‐positive breast cancer. N Engl J Med. 2019;380(7):617–28.

DOI Google Scholar

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2‐positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.

DOI Google Scholar

Krop IE, Kim SB, González‐Martín A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2‐positive advanced breast cancer (TH3RESA): a randomised, open‐label, phase 3 trial. Lancet Oncol. 2014;15(7):689–99.

DOI Google Scholar

Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac‐Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2‐positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open‐label phase 3 trial. Lancet Oncol. 2017;18(6):743–54.

DOI Google Scholar

McGregor BA, Sonpavde G. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial carcinoma. Expert Opin Invest Drugs. 2019;28(10):821–6.

DOI Google Scholar

Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee J‐L, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125–35.

DOI Google Scholar

Yu EY, Petrylak DP, O'Donnell PH, Lee J‐L, van der Heijden MS, Loriot Y, et al. Enfortumab vedotin after PD‐1 or PD‐L1 inhibitors in cisplatin‐ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single‐arm, phase 2 trial. Lancet Oncol. 2021;22(6):872–82.

DOI Google Scholar

Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, et al. Targeting HER2 with trastuzumab deruxtecan: a dose‐expansion, phase I study in multiple advanced solid tumors. Cancer Discovery. 2020;10:688–701.

DOI Google Scholar

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated her2‐positive breast cancer. N Engl J Med. 2020;382(7):610–21.

DOI Google Scholar

Cortés SK J, Chung W, Im S, Park YH, Hegg R, Kim MH, et al. Trastuzumab deruxtecan (T‐DXd) vs trastuzumab emtansine (T‐DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY‐Breast03 study. Ann Oncol. 2021;32(Suppl_5):S1283–346.

DOI Google Scholar

Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2‐positive gastric cancer. N Engl J Med. 2020;382(25):2419–30.

DOI Google Scholar

Tahara M, Okano S, Enokida T, Ueda Y, Fujisawa T, Shinozaki T, et al. A phase I, single‐center, open‐label study of RM‐1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma. Int J Clin Oncol. 2021;26(10):1812–21.

DOI Google Scholar

Weiss J, Glode A, Messersmith WA, Diamond J. Sacituzumab govitecan: breakthrough targeted therapy for triple‐negative breast cancer. Expert Rev Anticancer Ther. 2019;19(8):673–9.

DOI Google Scholar

Bardia A, Tolaney SM, Loirat D, Punie K, Oliveira M, Rugo HS, et al. A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple‐negative breast cancer (mTNBC). Ann Oncol. 2020;31(Suppl_4):S1142–215.

DOI Google Scholar

Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, et al. TROPHY‐U‐01: a phase II open‐label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum‐based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474–85.

DOI Google Scholar

Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, et al. Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study. Cancer Commun (Lond). 2021;41(11):1173–82.

DOI Google Scholar

Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, et al. Open‐label, multicenter, phase II study of RC48‐ADC, a HER2‐targeting antibody‐drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2021;27(1):43–51.

DOI Google Scholar

Xu H, Sheng X, Yan X, Chi Z, Cui C, Si L, et al. A phase II study of RC48‐ADC in HER2‐negative patients with locally advanced or metastatic urothelial carcinoma. J Clin Oncol. 2020;38(15_Suppl):e17113.

DOI Google Scholar

Zhou L, Xu H, Yan X, Chi Z, Cui C, Si L, et al. RC48‐ADC combined with toripalimab, an anti‐PD‐1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): preliminary results of a phase Ib/II study. J Clin Oncol. 2021;39(15_Suppl):4534.

DOI Google Scholar

Wang J, Liu Y, Zhang Q, Feng J, Fang J, Chen X, et al. RC48‐ADC, a HER2‐targeting antibody‐drug conjugate, in patients with HER2‐positive and HER2‐low expressing advanced or metastatic breast cancer: a pooled analysis of two studies. J Clin Oncol. 2021;39(15_Suppl):1022.

DOI Google Scholar

Coleman RL, Lorusso D, Gennigens C, González‐Martín A, Randall L, Cibula D, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG‐3023/ENGOT‐cx6): a multicentre, open‐label, single‐arm, phase 2 study. Lancet Oncol. 2021;22(5):609–19.

DOI Google Scholar

Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res. 2020;26(6):1220–8.

DOI Google Scholar

Liu F, Ke J, Song Y. T‐DM1‐induced thrombocytopenia in breast cancer patients: new perspectives. Biomed Pharmacother. 2020;129:110407.

DOI Google Scholar

Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti‐programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592–600.

DOI Google Scholar

Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M. Clinical toxicity of antibody drug conjugates: a meta‐analysis of payloads. Invest New Drugs. 2018;36(1):121–35.

DOI Google Scholar

Fontanella C, Bolzonello S, Lederer B, Aprile G. Management of breast cancer patients with chemotherapy‐induced neutropenia or febrile neutropenia. Breast Care (Basel, Switzerland). 2014;9:239–45.

DOI Google Scholar

Clifford K, Copeland A, Knutzen G, Samuelson E, Grove L, Schiavo K. Brentuximab vedotin: a nursing perspective on best practices and management of associated adverse events. Clin J Oncol Nurs. 2018;22(4):E103–14.

DOI Google Scholar

Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30‐positive peripheral T‐cell lymphoma (ECHELON‐2): a global, double‐blind, randomised, phase 3 trial. Lancet (London, England). 2019;393(10168):229–40.

DOI Google Scholar

Straus DJ, Długosz‐Danecka M, Alekseev S, Illés Á, Picardi M, Lech‐Maranda E, et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3‐year update of the ECHELON‐1 study. Blood. 2020;135(10):735–42.

DOI Google Scholar

Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open‐label, phase III ALFA‐0701 trial. Haematologica. 2019;104(1):113–9.

DOI Google Scholar

Barroso‐Sousa R, Santana IA, Testa L, de Melo Gagliato D, Mano MS. Biological therapies in breast cancer: common toxicities and management strategies. Breast. 2013;22(6):1009–18.

DOI Google Scholar

Fallah‐Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II‐positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011;57(22):2263–70.

DOI Google Scholar

Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging. 2014;15(3):324–31.

DOI Google Scholar

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603.

DOI Google Scholar

Xu B, Wang J, Fang J, Chen X, Han Y, Li Q, et al. Abstract PD4‐06: early clinical development of RC48‐ADC in patients with HER2 positive metastatic breast cancer. Cancer Res. 2020;80(4, Suppl):PD4‐06.

DOI Google Scholar

Sheng X, Zhou A‐P, Yao X, Shi Y, Luo H, Shi B, et al. A phase II study of RC48‐ADC in HER2‐positive patients with locally advanced or metastatic urothelial carcinoma. J Clin Oncol. 2019;37(15_Suppl):4509.

DOI Google Scholar

Liu Y, Lian W, Zhao X, Qi W, Xu J, Xiao L, et al. A first in‐human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2‐positive or HER2‐amplified who did not respond or stopped responding to approved therapies. J Clin Oncol. 2020;38(15_Suppl):1049.

DOI Google Scholar

Wang S, Xu F, Hong R, Xia W, Yu J‐C, Tang W, et al. Abstract CT053: BAT8001, a potent anti‐HER2 antibody drug conjugate with a novel uncleavable linker to reduce toxicity for patients with HER2‐positive tumor. Cancer Res. 2019;79(Suppl 13):CT053.

DOI Google Scholar

Hu X, Zhang J, Ji D, Xia G, Ji Y, Xiong G, et al. Abstract P1‐18‐16: a phase 1 study of ARX788, a HER2‐targeting antibody‐drug conjugate, in patients with metastatic HER2‐positive breast cancer. Cancer Res. 2020;80(4, Suppl):P1‐18‐16.

DOI Google Scholar

Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, et al. Cooperative targeting of melanoma heterogeneity with an AXL antibody‐drug conjugate and BRAF/MEK inhibitors. Nature Med. 2018;24(2):203–12.

DOI Google Scholar

Bruins WSC, Zweegman S, Mutis T, van de Donk N. Targeted Therapy With Immunoconjugates for multiple myeloma. Front Immunol. 2020;11:1155.

DOI Google Scholar

Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2‐positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double‐blind trial. Lancet Oncol. 2020;21(10):1283–95.

DOI Google Scholar

About this article

Publication history

Acknowledgements

Rights and permissions

Publication history

Received: 08 April 2022

Accepted: 23 April 2022

Published: 19 June 2022

Issue date: June 2022

Copyright

Acknowledgements

Authors of the Consensus (in alphabetical order of last name).

Jiayu Wang (Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Yongkun Sun (Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Yuqin Song (Department of Medical Oncology, Peking University Cancer Hospital), Tienan Zhu (Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences).

Consensus Professional Members (in alphabetical order of last name).

Yi Ba (Department of Digestive Oncology, Tianjin Medical University Cancer Institute and Hospital), Jinfei Chen (Cancer Center, Taikang Xianlin Drum Tower Hospital, Nanjing University School of Medicine), Xia Chen (Clinical Medicine Research Center, Beijing Tiantan Hospital, Capital Medical University), Wei Cui (Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Huaping Dai (Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China‐Japan Friendship Hospital, Capital Medical University), Jifeng Feng (Department of Medical Oncology, Jiangsu Cancer Hospital, Affiliated Cancer Hospital of Nanjing Medical University), Chenyan Gao (Center for Drug Evaluation, China Food and Drug Administration), Ying Han (Department of Digestive Oncology, Xijing Hospital of Digestive Diseases, Air Force Medical University), Xichun Hu (Department of Medical Oncology, Fudan University Shanghai Cancer Center), Jian Huang (Department of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine), Yuchen Jiao (State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Jie Jin (Department of Hematology, The First Affiliated Hospital of Zhejiang University, College of Medicine), Guohui Li (Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Bo Lan (Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Wei Li (Cancer Center, First Hospital of Jilin University), Mingsheng Liu (Department of Neurology, Peking Union Medical College Hospital), Yang Luo (Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Fei Ma (Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Hongzhi Mei (Department of Nursing Administration, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Quchang Ouyang (Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya Medical School, Central South University), Hongming Pan (Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University), Yueyin Pan (Department of Medical Oncology, The First Affiliated Hospital of University of Science and Technology of China), Jiajia Qiu (Department of Nursing Administration, Shanghai Cancer Center, Fudan University), Chi Shao (Department of Respiratory Medicine, Peking Union Medical College Hospital), Lin Shen (Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute), Erwei Song (Breast Tumor Center, Sun Yat‐Sen Memorial Hospital, Sun Yat‐Sen University), Yuqin Song (Department of Medical Oncology, Peking University Cancer Hospital), Tong Sun (Pathology Department, Yale School of Medicine/Yale New Haven Health/Bridgeport Hospital)，Yongkun Sun (Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Zhongsheng Tong (Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital), Jiayu Wang (Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Shuse Wang (Department of Medical Oncology, Sun Yat‐Sen University Cancer Center), Yanfeng Wang (Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Zhehai Wang (Department of Internal Medicine‐Oncology, Shandong Cancer Hospital), Lin Xia (Center for Drug Evaluation, China Food and Drug Administration), Binghe Xu (Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Zhao Yan (Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital), Shune Yang (Department of Breast Cancer and Lymphoma, Affiliated Tumor Hospital of Xinjiang Medical University), Zhimin Yang (Center for Drug Evaluation, China Food and Drug Administration), Yu Yao (Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an), Dingwei Ye (Department of Urology, Fudan University Shanghai Cancer Center), Yongmei Yin (Department of Medical Oncology, The First Affiliated Hospital of Nanjing Medical University), Xianglin Yuan (Department of Medical Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology), Huilai Zhang (epartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital), Li Zhang (Medical Oncology Department, Sun Yat‐sen University Cancer Center), Qifu Zhang (Department of Urology, Jilin Provincial Cancer Hospital), Qingyuan Zhang (Department of Medical Oncology, Harbin Medical University Cancer Hospital), Yanqiao Zhang (Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital), Zhiren Zhang (Department of Cardiology, Harbin Medical University Cancer Hospital), Bin Zhao (Department of Pharmacy, Peking Union Medical College Hospital), Aiping Zhou (Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Caicun Zhou (Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine), Jianfeng Zhou (Department of Hematology and Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology), Jun Zhu (Department of Lymphoma, Peking University Cancer Hospital and Institute), Tienan Zhu (Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences). Editorial Assistant: Lixi Li (Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College), Jiashu Han (MD program, Peking Union Medical College, Chinese Academy of Medical Sciences), Hewei Ge (Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College).

Rights and permissions

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.